1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Multiple Myeloma - Epidemiology Forecast to 2030

Multiple Myeloma - Epidemiology Forecast to 2030

  • September 2020
  • 200 pages
  • ID: 5962306
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Multiple Myeloma (MM)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

Multiple Myeloma (MM) Understanding
According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.
Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow. Treatment for multiple myeloma usually includes anti-myeloma medicines to destroy the myeloma cells or control cancer when it comes back (relapses) and medicines and procedures to prevent and treat problems caused by myeloma – such as bone pain, fractures, and anemia.
Epidemiology Perspective
The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MM epidemiology data are studied through MM possible division to give a better understanding of the Disease scenario in the 8MM.
The disease epidemiology covered in the report provides historical as well as forecasted MM epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of MM, Total Incident Cases of MM Segmented by Gender, Total Incident Cases of MM Segmented by Age, Total Cases of MM by Line of Treatment] scenario of MM in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.
MM Detailed Epidemiology Segmentation
• In the year 2017, the total incident case of Multiple Myeloma was 85,971 cases in the 8MM. The United States, in 2017, accounted for 30,271 cases (the highest number), which will probably rise by the year 2030.
• Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma was in Germany 7,337, in the year 2017. In the year 2017, the total incident cases of Multiple Myeloma was 7,504 in Japan. In the year 2017, the total incident cases of Multiple Myeloma was 19,536 in China, which might increase cases by 2030.
• In China, the total incident cases of Multiple Myeloma was 19,536 in 2017.
• In 2017, the 8MM total symptomatic cases of Multiple Myeloma was 75,679. In addition to this, the United States, in 2017, accounted for 26,647 cases.
• In gender-specific cases of Multiple Myeloma, males are frequently affected by Multiple Myeloma (accounted for approximately 55% of cases) in comparison to females.
• In age-specific cases of MM, in 2017, the most number of cases were seen in the age-group 65–74, followed by the age-group of 75–84 years, and 55–64 years.
• In the 8MM, the total cases of Multiple Myeloma by treatment line were 22,124 cases for frontline transplant eligible patients, 46,676 cases for frontline transplant ineligible patients, 42,244 cases for second-line patients, 22,092 cases for third-line patients, and 9,629 cases for fourth-line plus patients, in the year 2017

Scope of the Report
• The MM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The MM Report and Model provide an overview of the risk factors and global trends of MM in the seven major markets (8MM: United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China).
• The report provides insight about the historical and forecasted patient pool of MM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China, and China.
• The report helps to recognize the growth opportunities in the 8MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of MM.
• The report provides the segmentation of the MM epidemiology by total Incidence of MM in the 8MM.
• The report provides the segmentation of the MM epidemiology by total symptomatic cases of Multiple Myeloma in the 8MM.
• The report provides the segmentation of the MM epidemiology by Age and Gender in the 8MM.
• The report provides the segmentation of the MM epidemiology by Line-wise Treated Patient Pool of MM in the 8MM.

Report Highlights

• 11-Year Forecast of MM epidemiology
• 8MM Coverage
• Total Incident Cases of Multiple Myeloma in the 8MM
• Total Symptomatic Incident Cases of Multiple Myeloma in the 8MM
• Incident Cases of MM according to segmentation: Age, and Gender
• Treated cases of MM
KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over MM scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 8MM with respect to the patient population pertaining to MM ?
• What are the key findings pertaining to the Multiple Myeloma epidemiology across the 8MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Multiple Myeloma across the 8MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 8MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?

Reasons to buy
The MM Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global MM market
• Quantify patient populations in the global MM market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MM therapeutics in each of the markets covered
• Understand the magnitude of MM population by its severity
• The MM epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The MM Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China
Study Period: 2017–2030
Total Incident cases of MM in the United States was assessed to be 30,271 in 2017, and are expected to decline during the study period. Among the European 5 countries, the highest number of incident cases of Multiple Myeloma were in Germany 7,337, in the year 2017

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Kaposi Sarcoma Industry

  • $ 4950
  • April 2021
  • 138 pages

Abstract: - Global Kaposi Sarcoma Market to Reach $146.5 Million by 2027 - Amid the COVID-19 crisis, the global market for Kaposi Sarcoma estimated at US$125.4 Million in the year 2020, is projected ...

  • World
  • China
  • Cancer
  • Industry analysis

Global Doxorubicin Industry $ 5600 April 2021

Global Sarcoma Drugs Industry $ 5600 April 2021


ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on